The Jackson research group is focused on furthering our understanding of the pathogenesis of childhood asthma. Dr. Jackson has led studies aimed at identifying mechanisms of disease inception and exacerbation, and clinical trials to identify optimal treatment of asthma. The ultimate goal of his research is to develop and test effective approaches for the modification and prevention of asthma in children.
Dr. Jackson is the PI of the NIAID-funded Inner City Asthma Consortium (ICAC) which is focused on improving our understanding of mechanisms underlying the greater incidence and severity of asthma and allergic disease in urban children, particularly those living in poverty. The consortium aims to identify novel therapies to address the significant disease burden in this high-risk population.
Dr. Jackson is the PI of the Childhood Origins of ASThma (COAST) birth cohort study initiated in 1998. COAST has focused on host-environment interactions in the development of childhood asthma and has identified important relationships among type 2 inflammation, viruses and other microbes in the inception of asthma. COAST is currently part of the Childhood Respiratory and Environmental Workgroup (CREW) birth cohort consortium funded by NIH.
Dr. Jackson is also the UW-Madison site PI for the multi-center Oral Bacterial Extracts for the Prevention of Wheezing/Asthma (ORBEX) study funded by NHLBI, UW-Madison site PI for the multi-center Preventing Asthma in High-Risk Kids (PARK) study funded by NIAID, and a co-investigator and pediatric committee co-chair for the Precision Interventions for Severe and Exacerbation Prone Asthma (PrecISE) network funded by NHLBI.
In a recently published study, researchers Daniel Jackson, MD, professor, Division of Allergy, Immunology, and Rheumatology, and Matthew C. Altman, MD, University of Washington, two among the group of authors, showed that children with asthma …January 27, 2023
The team of investigators led by Daniel Jackson, MD, professor, Division of Allergy, Immunology, and Rheumatology, found a monoclonal antibody drug called mepolizumab decreased asthma attacks by 27% in children and adolescents who have a …September 15, 2022
The University of Wisconsin School of Medicine and Public Health has been selected as the national leadership center for a new clinical research network that will conduct pediatric asthma research in low-income urban settings around …May 5, 2021
Congratulations to Daniel Jackson, MD, Principal Investigator, and James Gern, MD, Co-Principal Investigator, for their 9-month supplemental funding on Inner City Asthma Consortium (ICAC3). The $401,456 supplement from the National Institutes of Health/National Institute of …December 3, 2020
James Gern, MD, Anne Marie Singh, MD, and Daniel Jackson, MD, Awarded NIH Grant with Johns Hopkins University
Congratulations to James Gern, MD, Principal Investigator, and Anne Marie Singh, MD, and Daniel Jackson, MD, Co-Investigators, on their new grant subaward through Johns Hopkins University and supported by the National Institutes of Health/National Institutes …October 30, 2020
- More News...